ALPN News and Press, Alpine Immune Sciences Inc. From 03/18/24

2024-03-18 16:38:49 ET Gainers: National CineMedia ( NCMI ) +8% . Inventiva ( IVA ) +6% . Alpine Immune Sciences ( ALPN ) +5% . Leslie's ( LESL ) +5% . Maxeon Solar Technologies ( MAXN ) +5% . Losers: DLocal  ( DLO...

2024-03-18 16:15:47 ET More on Alpine Immune Sciences Alpine Immune Sciences: Track Record Undermines Case For Latest Lead Drug Alpine Immune Looks Highly Interesting Except For The Price (Rating Upgrade) Alpine Immune Sciences Q4 2023 Earnings Preview Wolfe ...

-- Clinical data on povetacicept in IgA nephropathy will be updated at the upcoming WCN meeting, including follow up at 80 mg and initial data at 240 mg SC once every four-weeks -- -- Povetacicept advancing towards a pivotal phase 3 trial in IgA nephropathy and a phase 2 trial in systemic...

Lendway Inc. (LDWY) is expected to report for quarter end 2023-12-31 Hongchang International Co Ltd Com (New) (HCIL) is expected to report for Q4 2023 BioStem Technologies Inc (BSEM) is expected to report $0.47 for Q4 2023 Nicox SA (NICXF) is expected to report $-0.07 for Q4 2023 ...

2024-03-17 17:35:21 ET Major earnings expected after the bell on Monday include: StoneCo Ltd. ( STNE ) JOYY ( YY ) Bit Digital ( BTBT ) Xiaomi Corporation ( OTCPK:XIACF ) DLocal Limited ( DLO ) Read the full article on Seeking Alpha Fo...

2024-03-17 17:35:00 ET More on Alpine Immune Sciences Alpine Immune Sciences: Track Record Undermines Case For Latest Lead Drug Alpine Immune Looks Highly Interesting Except For The Price (Rating Upgrade) Wolfe starts Alpine Immune at outperform, cites upcoming catal...

2024-03-17 08:20:00 ET Wall Street has reached a notable lull in the pace of quarterly releases. Still, investors are eagerly anticipating important announcements from FedEx ( NYSE: FDX ) and a set of prominent consumer brands, such as Nike ( NYSE: NKE ), Lululemon Athl...

Alpine Immune Sciences, Inc. (NASDAQ: ALPN) is the focus of IBN's latest stock spotlight. The company's shares have moved -2.35% on the day to $36.13. Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunothera...

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced the Company will release fourth quarter and full year 2023 financial results on Monday, March 18, 2024,...

2024-03-07 15:30:54 ET Summary Alpine Immune Sciences has discarded two drug candidates since joining the Nasdaq in 2027, but its stock price has risen >200% in six months owing to its latest lead candidate. Povetacicept has shown promising results in a Phase 2 study for the tr...